Total Payments
$1,563
2020 Payments
$220.00
Companies
4
Transactions
14
Payment Breakdown by Category
Research$1,290 (82.6%)
Food & Beverage$272.75 (17.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,290 | 11 | 82.6% |
| Food and Beverage | $272.75 | 3 | 17.4% |
Payments by Type
Research
$1,290
11 transactions
General
$272.75
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,290 | 11 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $99.47 | 1 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $97.06 | 1 | $0 (2017) |
| Allergan Inc. | $76.22 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $220.00 | 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($220.00) |
| 2019 | $1,170 | 9 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,070) |
| 2017 | $173.28 | 2 | Otsuka America Pharmaceutical, Inc. ($97.06) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/22/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/22/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/21/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $120.00 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 05/29/2019 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $99.47 | General |
| 05/11/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $57.60 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | ||||||
| 05/10/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $133.76 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | ||||||
| 05/10/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | ||||||
| 05/10/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | ||||||
| 05/10/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $22.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | ||||||
| 05/09/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $586.96 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | ||||||
| 05/09/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $133.76 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | ||||||
| 05/09/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $36.25 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | ||||||
| 11/13/2017 | Allergan Inc. | NAMENDA XR (Drug), NAMZARIC | Food and Beverage | In-kind items and services | $76.22 | General |
| Category: NEUROSCIENCE | ||||||
| 06/07/2017 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $97.06 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER TRIAL 405-201-00013 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,070 | 8 |
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $220.00 | 3 |
About Dr. John Prater, D.O
Dr. John Prater, D.O is a Psychosomatic Medicine healthcare provider based in Phoenix, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1801014378.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Prater, D.O has received a total of $1,563 in payments from pharmaceutical and medical device companies, with $220.00 received in 2020. These payments were reported across 14 transactions from 4 companies. The most common payment nature is "" ($1,290).
Ad
Practice Information
- Specialty Psychosomatic Medicine
- Other Specialties Psychiatry
- Location Phoenix, AZ
- Active Since 04/23/2007
- Last Updated 06/24/2024
- Taxonomy Code 2084P0015X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1801014378
Products in Payments
- REXULTI (Drug) $317.06
- NAMENDA XR (Drug) $76.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.